A 37-year-old woman, a financial analyst, came to the office with an 8-day history of dizziness. A certified diver, she had been scuba diving in the ocean 10days earlier. She had no difficulty clearing her ears, even after several dives as deep as 60 feet. She had 44°C RIGHT 16°/SEC RIGHT BEATING undergone decompression in the approved manner.
The patient reported that she developed a headache soon after her last dive. She said the headache felt like it was "wrapped around my head." The day after her last dive, she flew home and did not feel well. The next day, she became lightheaded and dizzy . She sought treatment and was placed in a hyperbaric chamber for 10 hours. Afterward, she felt better for approximately 24 hours, but then her symptoms returned. She again underwent hyperbaric therapy, but she did not improve.
The patient said her dizziness took on different characteristics depending on the situation. When she was standing or walking, she felt as if she was about to fall down. When she was sitting or lying down, she felt "woozy." She felt best when she was lying down. She also complained of binaural fullness, more so on the right, but she was not sure how long it had been present. The sensation of From Neurotologic Associates, P.C., New York City.
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ing, and electronystagmography detected no spontaneous, positional, or neck-torsion nystagmus. The results of an alternate binaural bithermal caloric test were normal, with a reduced vestibular response right of 19% and a directional preponderance of 17%. Simultaneous binaural bithermal stimuli evoked a type 2 response, indicating that the patient had a reduced vestibular response on the right. A metabolic evaluation revealed a blood sugar level of 40 mg/dl and evidence ofhyperinsulinemia. Ultrathinlayer, small-pixel computed tomography of the temporal bones yielded findings consistent with inner ear otosclerosis. The patient was placed on a diet to address her metabolic factors , and she was prescribed etidronate and calcium to treat the otosclerosis. At the 2-month follow-up visit, the patient's dizziness, headache, aural fullness, focusing problem, and photophobia had completely resolved, and her concentration had improved. However, the pain in her neck and ears continued; she felt worse during her menstrual period, a finding commonly seen in women with otosclerosis. Sinusoidal vertical -axis rotation testing detected an abnormal symmetry, which is evidence of a continuing vestibular problem. A very low dose of desipramine was added to her regimen. As a tricyclic antidepressant, desipramine has sympathomimetic and anticholinergic effects, both of which are useful in suppressing vestibular symptoms.
The patient returned 3 months later and reported that her neck pain had disappeared and her ear pain was diminished. However, findings of abnormal symmetry on a follow-up sinusoidal vertical-axis rotation test continued to indicate that she had a peripheral vestibular disorder. She had also experienced palpitations as a result of the desipramine, so she was switched to Vertigoheel.
Six months later, the patient was almost symptom-free. Findings on a repeat sinusoidal vertical-axis rotation test were nearly normal. She was switched from etidronate to risedronate and continued on calcium. She returned 3 months later essentially symptom-free. Five months later, she had successfully discontinued the Vertigoheel. She remained symptom-free 6, 12, and 18 months later and was able to discontinue the remainder of her oral treatment regimen.
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Themorepolen! corucosteroids ha'm been sha:.nto be ! C-r a l og~c a~t er der malappl icationinIaf.a atory a:1imals The most commonly reported adverse events in seasonal allergic rhinitis and nonallergic vasomotor rhinitis patients 12 years of age and older were bitter taste, headache, somnolence, and nasal buming. The adverse event profile in seasonal allergic rhinitis patients 5 to 11 years of age was similar to that in the adult population. Discontinuation rates due to adverse events in patients taking ASTELIN Nasal Spray in the seasonal allergic rhinitis and nonallergic vasomotor rhinitis clinical trials were no different than those for placebo. r~l f T~~~~~r yUĩ~~d~c a t e d for the treatment of thesymptoms 'of seasonal allergicrhinitis such asrhi norrhea! sneezinq, and nasal pruritusin adultsand chi ldren 5 yearsand older, and forthe treatmentof the symptoms ofvasomotorrhinitis. suc h asrhinorrhea, nasalcongestion and post nasaldripin adultsandchildren12 years and older.~l n~A~~~~~~~~sScon t r a in d jcat ed in patients withaknown hypersensitivitytoazelastinehydrochlori deor any of itscomponents.
PRECAUTIONS
.
. ActivitiesRequiring Mental Alertness : tnclinical trial s, the occ u~rence of somnolencehas beenreported m.some patients takingAstelin· NasalSpray; due caution should thereforebeexercise d when drivinga car or operatmp potentlallydang.e.rous machinery. Concurrent useof Astelin e Nasal Sp raywithalcohol or other CNSdepressants should be avoidedbecauseaddfional reductions in alertness andadditional impairmentof CNS perf ormancemay occur. InformationforPatients: PatientsshouldbeinstructedtouseAstelin' NasalSpray onlyasprescribed. For theprop eruseofthe nasal spray and to attain maximum improvement, the patient should read and follow carefully the accom panying pat ient instructions.Patientsshouldbeinstructedtoprimethedelivel)' systembefore initialusea~d afterstorage for3 orm~re days(see PATIENT INSTRUCTIONSFORUSE) . Patienls shouldalsobeinstructedtostore thebott leupnght atroom temperature With thepump tightly closed andout of thereach of children. In case of accidental ingestionby a youngchild,seek prof essi onal assistanceor contact a poison control center immediatel y.
Pa tients shouldbeadvisedagainst theconcurrentuseof Astelin ll Nasal Sp~ay withother ant i hi s tami n~s without consulti nqa physician. Patientswhoare,or mayb e c o~e , pregnantshould be told that thls product shouldbe u?edrnpregnancyor.durmg lactation only if the potential benefit justifies thepotential risks to the.fetu. s or nur sl~9 infant. Patients shouldbe advised to assess thei r individual responses to Asteli n ll Nasal Spray before engagmg In anyactivityr eq Ul~l ng mentalalertness, suchas drivi nga car oroper ating machinery, Patientsshould be advised thattheconcurr ent useofAstelln-NasalSpray Withalcoholor otherCNSdepressants maylead to additional reductions inalertness and impairment ofCNSperformanceand shouldbeevoiced (seeDrug Interactions).
. DrugInteractions: Concurrent useofAstelin' Nasal Spraywithalcohol or other CNSdepressantsshould beavoided because additional reductions in alert ness andadditional impairment ofCNS performance may occur.
Cimet idine (40 0 mg twice daily) incr easedthe mean. Cmaxand A U~of or?lIy administered azelastineh y d ro c hl o r i d~(4 .mg t\.vicedaily)by approximately65%.Hanlfidinehydrochlonde(150mg twicedally) hadnoeffect onazelastme pbarmacckinetics.
Interaction studies investigating thecardiac effects, asmeasuredbythecorrected orinlerval(OTc) ,~f concomitantlyad~i ni ste rõ ralazelastinehydrochlorideand eryt hromyc in or ketoconazolewereconducted. Or al erythromycm(5q Omgthree tm~es dally for seven days) had no effect on azetasnne pharmacokinet ics or aTc based on analyses of serial electrocardoqrams, Ketoconazole(200 mgtwicedaily forsevendays) interferedwiththemeasurement of azelasunepl asmaconcentrations;however, noeffectson aTc wereobserved.
No significant pharrnacokinetlc interaction wasobserved with the coad mi nistration 01an oral 4 mg dose of azelastine hydrochloride twi cedai lyand theophylline300mgor400mg twice daily.
Carci nogenesis, Mutagenesis, Impairment of Fertili ty:
In 2 year carcinogenicity studies in rats a~d mi ce, az~l asti n e hydrochloridedidnotshowevidenceof carcinogenicityatora l doses upto30mglkga~d 25mglkg, r e sp ec t l v~l y (approximately 240 and 100 times themaximumrecommended daily intranasaldose in adultsand childrenon a mg/m 1 baSIS).
Azelasl inehydrochlorideshowed nogenot oxiceff ects in theAmes test, ONA repair test, mouse lymphoma forwardmut alion assay, mousemicronucleus test,or chromosomal aberration testinratbone marrow.
. Reproducti onand ferti litystudies inratsshowed noeffectsonmaleorfemal eferti lity.at oral doses upto30m~g (ap proxl m~tel y 240 times themaxi mumrecommendeddai lyintranasal doseinadultsonamglm 1 baSIS ).At68.6 mglkg(approximately560 tmes themaxi mumrecommendeddail y intranasal dose inadultsonamg/ m 1 basis), thedur ationof estrouscycles.was p ro l~n g ed and copulatory activity and the number of pregnancieswere decreased. The numbers of corpo ra lutea and Impl antatIons were decreased; however , pre-implantation loss wasnotincreased. Pregnancy Category C: Azelastinehydrochloridehasbeenshown to causedevelopmental toxicity. Tr eatment of mi cewithan oral dose of 68.6 mglkg (approxi mately 280 times the maximum recomm endeddaily intranasal dose in adultson a mg/m l basi s) caused embryo-fetal death, malf ormations (cleft pal ate; short or absent tai l; fused, absent or branchednbs), d e l~y ed oss ificat ion and decreased fetal weight.This dose alsocaused maternal toxicity as. evidenced by dec reased body w el g~t. Neither fetal nor maternal effects occurred at a dose of 3 mglkg (approximately 10 times the maximum recommended dally intranasaldose in adultson a mg/m 1 basis).
Inrats, anoral dose of 30mg/kg(approximately 240 timesthemaximum recommendeddailyintranasal dose in adultson a mg/ m 1 basi s)caused malformations (oli go-and brachydactylia), delayed ossification and skeletal variat ions, in the absence of maternal toxicity. At68.6 mglkg (approximately 560 times themaximum recommended daily lntranasaldose in adul ts on a mg/m 1 basis) azelastine hydrochloride alsocaused embryo-fetal deathand decreasedfetalweight; however,the 68.6m.g/kg dosecausedseverematernal toxicity. Neit her fet al nor maternal effec tsocc urredat a dos e of 3 mglkg(appmximately 25 times themaximumrecommended dai ly intranasal dosein adults on a mglm 1 basis).
Inrabbits,oraldoseof 30mglkgandgreater (approxi mately 500times themaximumrecommendeddaily intranasal dose in adults onamg/m l basis) caused abortion,delayedossification and decreasedfetal weight; however , these doses alsoresulted inseverematernaltoxici ty. Neither fetalnor maternal effects occ urredat adose of0.3mglk g(approximately5times themaximum recommendeddailyintranasal dose in adultson a mg/m' basis).
There arenoadequate and well-controlled clinical studiesin pregnantwomen.Astelin t Nasal Sprayshould be used during pregnancyonly if thepotenti al benefit justifi es thepotenti al risk tothe fetus. NursingMot hers: It isnotknow nwhetherazelastinehy. drochlorideis excreted inhumanmilk, Becausemanydrugs areexc reted inhumanmilk, caution shouldbe exerci sed whenAstehn-Nasal Spray is admi nistered toa nursing woman. Pediatric Use:Thesafetyandeffectiveness ofAstelin-Nasal Spray at adose of1spray pernostrilw icedailyhasbeenestablished forpatients 5 through 11yearsof age for the treat ment of symptoms of seasonal allergicrhinitis. The safetyofthis dosageof Astelin" Nasal Spray was established in well-controlled studiesofthis dosein 176 patients 5 to12 years of agetreated forup to 6 weeks.Theefficacy ofAstelin 8 NasalSpray at this doseis basedonan ext rapolation of thefindingofefficacy in adults,on thelikelihood that thediseasecourse, pathophysiol ogy andresponsetotreatment aresubstantiallysimilar inchildrencompared toadults, andon supportivedatafrom controlled clinical trial s inpatients 5 to 12yearsof ageatthedoseof 1sprayper nosfru twicedail y.The safety andeffect iveness of Astelin-Nasal Sprayinpatients below theageof5 years havenot beenestablished. Geriatric Use: Cli nical studies of Astelin-Nasal Sp raydidnot includesuffic ient numbersof subjects aged65andover todet ermine whe therthey respond diffe rently fromyounger subjects. Other report edclinical experience has notidentified differences in responses betweentheelderlyand younger patients. In general,dose selection for an elderlyp~t i ent should be0Iutious, .usually startingat thelowend of thedosingrange,refl ectingthegreater frequencyofdecreasedhepatic.renal ,or cardiac functi on,and of concomitant disease orotherdrug therapy. AOVERSEREACTIONS Seasonal Allergic Rhinitis Adverseexperience information forAstelin-NasalSp ray isderivedfromsixwell -contr oll ed,2-day to8-weekclinicalstudies which included 391patientswho recei vedAs telin e Nasal Spray atadoseof2sprayspernostri l twi cedai ly. Inplacebo-controlledefficacy trials, the inci dence of di scontinuation due toadversereactions inpatients receivi ngAs te l i n~Nasal Sp raywas notsignificantly different from vehicleplacebo(2.2%vs2.8%, respectively).
In these clinicalstudies, adverseevents that occ urred statistically significantly more often in pati ent s treated withAstelin" Nasal Spray versus vehide placeboinduded bittertaste (19.7%vs0.6%),somnolence (11.5%vs5.4 %),wei ght incr ease(2.0%vs0%), and myal gia(1.5%vs0%) .
The following adve rseeventswere reported with frequencies~2 % in the Astelin s NasalSpray treatment group and more f r e Qu e~t1 y thanplacebo in short-term($2 days) and long-term(2-8weeks)clinical trials. Atotal of 176 patients5 to 12 years of age wereexposed toAstelin" Nasal Sprayat adoseof 1spray eachnostril twiced~i l y in 3placebo-controlled studies. In these studies, adverseeventsthat occurred morefrequently inpatient s treated withAst elln'" Nasal Spray than withpl acebo,andthat werenot representedintheadult adverse eventtable above includerhinitis/coldsymptoms (17 .0%vs9.5%),cough (11. 4%vs8.3% ),conj unctivitis (5.1%vs 1.8%), and asthma (4. 5%vs 4.1%).
. The following eventswere observedinfrequently « 2%andexceedi ng placebo inci dence) in patientswho recei vedAstelm" Nasal Spray(2sprays/nostril twicedai ly) inU.S. clinical trials. cardiovascular: flushing, hypertension,tachycardia. Dermatological : contact dermatitis, eczema, hair and folli cleinfection, furunculosis. Digestive: constipation, gastroenteritis, glossitis, ulcerative stomatitis, vomiting, increased SGPT, aphthous stomat itis. Metabolicand Nutriti onal : increasedappeti te. Musculoskeletal: myalgia, temporomandibul ar disl ocation. Neurological: hyperkinesia, hypoesthesia, vertigo. Psychol ogi cal : anxiety, depersonalizati on, depression, nervousness,sleep disorder, thinki ngabnormal. Respirato ry: bronchospasm, coughing,throat burning, laryngitis. Special Se nses: conj unctivitis, eye abnormality,eyepain, wateryeyes, taste loss. Urogenital: albuminuria,amenorrhea, breast pain, hematurta.tncreased urin aryIrequency, . . . . WholeBody: allergicreaction, back pain, herpes simplex, viral Infection, malai se, pai nmextrerniues, abdomlOal pain. AOVERSE REACTIONS VasomotorRhiniti s Adverse experienceinformation forAstelin S Nasal Sprayis derived fromtwo pl ac e bo~c on t r~l I ed cli nical studiesw hi c~i n~l ud ed 216 patientswhoreceivedAstelin S Nasal Sprayat adose of2 sprays pernostril twicedally for upto28days.The incidence of disconti nua tion duetoadversereactions inpatientsreceivingAstelin-NasalSpray was notdifferent fromvehicle placebo (2.8% vs 2.9%, respectively). The following adverseevents were reported with frequencies 2: 2% in the Astelin S Nasal Sp raytreatment group and more frequently thanplacebo. Events observed infrequently « 2% and exceeding placebo incidence) in pati ent s who received Astelin!> Nasal Sp r~y (2sprays/nostril twicedaily) in U. S. clinical trials in vasomotor rhini tis weresimilar to thoseobservedin U.S. clinical trials 10 seasonal allergic rhinitis.
In controlled trials invol ving nasal and oral azelastine hydrochloride formulations, there were infrequent occurrences of hepati c transaminaseelevations.Theclinica l rel evanceofthesereport s has not~e en establishe. d. .
. Inaddition,the followi ng spontaneousadve rseeventshave been reported dUringthe rnarketinqofAste.hn* Nasal Spray and causal relationship withthedrugis unknown: anap hylactoid reaction, application site irritation, chest pam, nasal conqesnon, confusion,diarrhea, dyspnea, facial edema, involuntarymuscle contract ions, paresthesia, parosmia, pruritus, rash,tol erance, uri naryretention, visio n abnor mal and xerophthalmia. OVEROOSAGE There have been no reported overdosages withAstelin" NasalSpray. Acute overd osage by adults with this dosage form is unli kel y to result in clinically significant adverse events, other thanincr easedsomnolence,since one bottle o.fAstelin S N a~al Spray contains 17 mgof azelastinehydrochlorid.e-. Clinicalstudies in adultsw~th singledosesoftheora l fo rm U l ati o~of azelasnne hydrochloride (up to 16 mg) have not resulted In increased incidence of s erl o~s adve rseevents. General ? U p p o rt IV~~eas~r es should be employed if overdosage occurs.ThereISno known antidote toAstehn-NasalSpray. Oral Ingesti onof antlhlstamlOes hasthepotential tocauseseriousadverse effe ctsin youngchildren.Accordingly, Astelin 8 NasalSpray shouldbekeptout of the reachofchildren. Or aldosesof 120 mglkg and greater (approxi mately 460times themaximum recommendeddaily intranasal dose in adults and children ona mg/m 1 basis) were lethal in mi ce. Responses seenprior to death wer e tremor, convulsions, dec reased muscletone,and salivation.In dogs, singleoral dosesas hi gh as 10mglkg (approximately260 times themaximum recomm ended dail y intranasal dose in adults and children on a mg/m 7 basis) were well toler ated, but single oral doses of 20 mglkgwere lethal . OOSAGE AND ADMINISTRATION Seasonal Allergic Rhinitis . . . . ... Therecommendeddoseof Astelin-NasalSpray in adultsandchildren12 yearsandolder Withseasonal allerqlcrhi nitiSIStwo spraysper nos tril twice dai ly.The recommended dose of Astelin S Nasal Spray in children 5 years to 11yearsof age is one spray pernostril twicedaily.
Vasomotor Rhinitis
The recommendeddose of Astelin-Nasal Spray in adults and children 12 years andolder withvasomotor rhinitis is two sprays pernostriltwicedaily.
. Befor e initial use, thescrew cap on the bottl e shoul d be replaced with the pump U~i t and the delivery systemshould be primed with 4 sprays unt il a fine mist appears. When 3 or more dayshave elapsed smce thelast use, thepumpshouldbe reprimed with2 sprays or until a fine mi st appears. CAUTION: Avoid spraying in the eyes. Directions for Use: Ill ustratedpatient instructions for prop er useaccompanyeach package of Astel in' · NasalSpray. HOW SUPPLIED Ast elin-(azelastnehydrochloride) Nasal Spray, 137 mcg,(NOC0037-0241·10)is suppli edasapackagecont aininga total of 200 metered spraysin twohigh-density polyethylene(HOPE) bottles fitted with screw caps,Aseparate metered-dose spray pumpunit anda leafletofpatient instructions arealsoprovided.The spray pumpunit is packaged in apolyethylene wrapper andconsists of a nasal spray pump fitted with a bl ue safetyclipanda blueplasti c dust cover. EachAst eli n-(azetastinehydrochl oride) NasalSpray, 137 mcg, bott lecontains 17 mg(1 mglmL) of azelastineh y d ro chl o r i~e to be usedwith the suppliedmetered-dose spray pump unit. Eachbottle can deliver100 metered sprays. Eachspraydeli ver s a mean of 0.137 mLsol ution containing 137 mcgof azelastinehydrochlori de. ATTENTION: The imprintedexpirationdateapplies to the pro duct in thebottles with screw caps. After thespray pumpis inserted into the first bottl e of the dispensingpackage, bothbottlesof prod uct should bediscardedafter 3 months, not to exceed theexpiration date imprintedonthe label. Storage:Sto reat controll edroomtemperature 20"-25"C(68"-77"F) . Protect from freezing. Somerset, New Jersey 08873
